Adicet Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Adicet Bio, Inc. on June 6, 2022. The filing discloses emerging interim data from the Company's Phase 1 clinical trial of ADI-001, a gamma delta T cell therapy, for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL). The data reflects a cut-off date of May 31, 2022.
Key Clinical Metrics and Financial Status
Clinical Efficacy (N=8 evaluable patients):
- Overall Response Rate (ORR): 75% across all dose levels; 80% in dose levels 2 and 3 combined.
- Complete Response (CR): 75% across all dose levels; 100% in patients who previously relapsed after anti-CD19 CAR T therapy (3/3).
- Durability: 50% (2 of 4) of evaluable patients with at least six months of follow-up remain cancer-free.
- Patient Profile: Heavily pretreated with a median of 4 prior therapies and a median International Prognostic Index (IPI) score of 4.
Safety Profile:
- No dose-limiting toxicities (DLTs), graft vs. host disease (GvHD), or Grade 3+ Cytokine Release Syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported.
- Adverse events of special interest included Grade 1 CRS and Grade 1 ICANS, both resolving within 24 hours without intervention.
- One patient in Dose Level 1 died of COVID-19 pneumonia complications, deemed unrelated to ADI-001.
Financial Metrics: The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on clinical trial updates.
Material Changes and Outlook
Protocol Amendments and Next Steps:
- The protocol was amended to include a new Dose Level 4 (1 billion CAR+ cells) and potential consolidation dosing at Dose Level 3.
- The Company expects to finalize the recommended Phase 2 dose in the second half of 2022.
- Enrollment backfilling for Dose Level 3 is expected in the second half of 2022.
- At least one additional clinical update is expected in the second half of 2022.
Regulatory and Development Timeline:
- Discussions with the FDA and EMA regarding pivotal study design and potential Biologics License Application (BLA) pathways are planned.
- Initiation of at least one potentially pivotal study is targeted for the first half of 2023.
- The Company plans to file one new Investigational New Drug (IND) application every 12-18 months, including one in 2023, from its pipeline of six additional internal gamma delta T cell therapy programs.
Investor Verification Checklist
- Sample Size Limitations: Verify the statistical significance of the 75% ORR given the small sample size (N=8) and the early nature of the data.
- Durability Confirmation: Monitor future updates to confirm the durability of responses, particularly for the 50% of patients with six-month follow-up.
- Safety in Larger Cohorts: Assess whether the favorable safety profile (no Grade 3+ CRS/ICANS) holds as the trial expands to higher doses (DL4) and larger patient numbers.
- Regulatory Alignment: Track the outcome of discussions with the FDA and EMA regarding the design of pivotal studies and the path to BLA/MAA.
- Capital Requirements: Review the Company's most recent 10-K or 10-Q filings to assess cash runway, as this 8-K does not disclose financial liquidity or funding needs for the expanded Phase 1 and upcoming pivotal studies.